Testing Treatment for Prostate Cancer
common.study.values.description
“A Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer”
The purpose of this study is to determine the benefit and safety of relugolix 120 mg orally once daily for 48 weeks on maintaining serum testosterone suppression to castrate levels (a?$ 50 ng/dL [1.7 nmol/L] in participants with androgen-sensitive advanced prostate cancer.
common.study.values.location
participant.ui.study.affiliations-map.online-study.header-virtual
participant.ui.study.affiliations-map.online-study.text
common.study.values.methods
common.study.methods.has-drugs-yes
common.study.methods.is-healthy-yes
Drug - Relugolix
Relugolix 120 mg tablet administered orally once daily following an oral loading dose of 360 mg on Day 1
Drug - Leuprolide Acetate
Leuprolide acetate depot suspension, 22.5 mg (or 11.25 mg in some Asian countries), every 3-months by subcutaneous or intramuscular injection
participant.views.study.view.additional
participant.views.study.view.scientific-title
HERO: A Multinational Phase 3 Randomized, Open-label, Parallel Group Study to Evaluate the Safety and Efficacy of Relugolix in Men With Advanced Prostate Cancer
common.study.values.clinical-trial-id
NCT03085095
participant.views.study.view.id
PdyvPe
